When most people think of cannabis users, they probably think mainly of the younger generations. But it’s actually the 45 to 64 age group who show the highest proportion of household spending on cannabis.
The federal government says grass and guns don’t mix, and that is putting gun owners who use medical marijuana — and the strongly pro-gun-rights administration of President Donald Trump — in a potentially uncomfortable position.
The Australian government announced today that it would allow medicinal cannabis exports. It said the move would boost opportunities for domestic manufacturers, noting that a strong industry would mean Australian doctors having high-quality products to prescribe to their patients.
A key problem in caring for patients with psychosis is that they are often reluctant to take antipsychotic drugs because of concerns about side effects – but cannabis-based treatments could change this
The World Health Organization (WHO) has recommended that cannabidiol (CBD) should not be scheduled as a drug by the United Nations. In November, the WHO Expert Committee on Drug Dependence (ECDD) convened in Geneva, Switzerland to discuss the potential dangers of 17 different drug substances, including cannabidiol.
Like any other patient, medical marijuana patients lean in the direction of lower cost medications over higher priced brand names, and specials, customer loyalty programs, and other seasonal offers are an attractive option to patients on a budget.
Some are tapping into marijuana’s psychoactive effects to quiet the brain during intense yoga sessions and other mind-oriented sports, such as running or swimming. Others use cannabis products that don’t make them high but, instead, create effects that users insist help them train harder and longer, with less pain and faster recovery times.
All African nations are capable of cultivating medicinal marijuana to exploit a growing international acceptance of cannabis-based medicines.
The current global market for marijuana products is US$3 billion and is expected to rise to US$56 billion as more countries and US states join the legalisation trend.